{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:13:10Z","timestamp":1746591190232,"version":"3.40.5"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11864-025-01311-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:14:12Z","timestamp":1745219652000},"page":"385-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardio-Oncology and Breast Cancer Therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Rohit","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aderonke","family":"Adeniyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenica N.","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Van Buren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Dittus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara K.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"1311_CR1","doi-asserted-by":"publisher","unstructured":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation. Accessed June 18, 2024. https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"41","key":"1311_CR2","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"22","key":"1311_CR3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777.","journal-title":"Circulation"},{"issue":"2","key":"1311_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350\u201361. https:\/\/doi.org\/10.1002\/ejhf.1631.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1311_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11897-024-00681-x","volume":"21","author":"SW Romann","year":"2024","unstructured":"Romann SW, Giannitsis E, Frey N, Lehmann LH. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. Curr Heart Fail Rep. 2024;21(6):505\u201314. https:\/\/doi.org\/10.1007\/s11897-024-00681-x.","journal-title":"Curr Heart Fail Rep"},{"key":"1311_CR6","unstructured":"Cardio-oncology \u2014 A marriage of cardiology & oncology - Mayo Clinic. Accessed January 11, 2025. https:\/\/www.mayoclinic.org\/medical-professionals\/cancer\/news\/cardio-oncology-a-marriage-of-cardiology-oncology\/mac-20491245"},{"issue":"1","key":"1311_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcm.2019.01.006","volume":"30","author":"A Padegimas","year":"2020","unstructured":"Padegimas A, Clasen S, Ky B. Cardioprotective Strategies to Prevent Breast Cancer Therapy-Induced Cardiotoxicity. Trends Cardiovasc Med. 2020;30(1):22\u20138. https:\/\/doi.org\/10.1016\/j.tcm.2019.01.006.","journal-title":"Trends Cardiovasc Med"},{"issue":"20","key":"1311_CR8","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1311_CR9","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.31557\/APJCP.2021.22.9.2847","volume":"22","author":"A Wihandono","year":"2021","unstructured":"Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Asian Pac J Cancer Prev. 2021;22(9):2847\u201353. https:\/\/doi.org\/10.31557\/APJCP.2021.22.9.2847.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"21","key":"1311_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022.","journal-title":"Eur Heart J"},{"key":"1311_CR11","doi-asserted-by":"publisher","unstructured":"Hundley WG, D\u2019Agostino R, Crotts T, et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. NEJM Evidence. 2022;1(9). https:\/\/doi.org\/10.1056\/EVIDoa2200097","DOI":"10.1056\/EVIDoa2200097"},{"issue":"6","key":"1311_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023;330(6):528\u201336. https:\/\/doi.org\/10.1001\/jama.2023.11887.","journal-title":"JAMA"},{"issue":"6","key":"1311_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9(6):515\u201325. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"1311_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179452","volume":"12","author":"A Ludke","year":"2017","unstructured":"Ludke A, Akolkar G, Ayyappan P, Sharma AK, Singal PK. Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C. PLoS ONE. 2017;12(7): e0179452. https:\/\/doi.org\/10.1371\/journal.pone.0179452.","journal-title":"PLoS ONE"},{"key":"1311_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1521020","volume":"2017","author":"D Cappetta","year":"2017","unstructured":"Cappetta D, De Angelis A, Sapio L, et al. Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity. Oxid Med Cell Longev. 2017;2017: e1521020. https:\/\/doi.org\/10.1155\/2017\/1521020.","journal-title":"Oxid Med Cell Longev"},{"key":"1311_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"307","author":"M Songbo","year":"2019","unstructured":"Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41\u20138. https:\/\/doi.org\/10.1016\/j.toxlet.2019.02.013.","journal-title":"Toxicol Lett"},{"issue":"11","key":"1311_CR17","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342. https:\/\/doi.org\/10.1038\/nm.2919.","journal-title":"Nat Med"},{"issue":"12","key":"1311_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103.","journal-title":"Heart"},{"issue":"2","key":"1311_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/CIRCRESAHA.117.312395","volume":"122","author":"D Bernstein","year":"2018","unstructured":"Bernstein D. Anthracycline Cardiotoxicity. Circ Res. 2018;122(2):188\u201390. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.312395.","journal-title":"Circ Res"},{"key":"1311_CR20","doi-asserted-by":"publisher","unstructured":"Sawicki KT, Sala V, Prever L, Hirsch E, Ardehali H, Ghigo A. Preventing and Treating Anthracycline Cardiotoxicity: New Insights. Annual Review of Pharmacology and Toxicology. 2021;61(Volume 61, 2021):309\u2013332. https:\/\/doi.org\/10.1146\/annurev-pharmtox-030620-104842","DOI":"10.1146\/annurev-pharmtox-030620-104842"},{"key":"1311_CR21","unstructured":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines | European Heart Journal | Oxford Academic. Accessed May 5, 2024. https:\/\/academic.oup.com\/eurheartj\/article\/37\/36\/2768\/2197413?login=false"},{"key":"1311_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;1257:181\u201392. https:\/\/doi.org\/10.1007\/978-3-030-43032-0_15.","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"1311_CR23","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869\u201379. https:\/\/doi.org\/10.1002\/cncr.11407.","journal-title":"Cancer"},{"issue":"2","key":"1311_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5603\/CJ.a2020.0062","volume":"29","author":"RM Caballero","year":"2022","unstructured":"Caballero RM, Antol\u00edn JMS, Hern\u00e1ndez RMJ, et al. Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines. Cardiol J. 2022;29(2):228\u201334. https:\/\/doi.org\/10.5603\/CJ.a2020.0062.","journal-title":"Cardiol J"},{"issue":"3","key":"1311_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-007-9803-5","volume":"107","author":"G Dranitsaris","year":"2008","unstructured":"Dranitsaris G, Rayson D, Vincent M, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008;107(3):443\u201350. https:\/\/doi.org\/10.1007\/s10549-007-9803-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1311_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(12)70525-9.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1311_CR27","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1200\/JCO.2004.03.098","volume":"22","author":"J Bonneterre","year":"2004","unstructured":"Bonneterre J, Roch\u00e9 H, Kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol. 2004;22(15):3070\u20139. https:\/\/doi.org\/10.1200\/JCO.2004.03.098.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1311_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jcmg.2015.11.024","volume":"9","author":"HK Narayan","year":"2016","unstructured":"Narayan HK, French B, Khan AM, et al. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. JACC Cardiovasc Imaging. 2016;9(10):1131\u201341. https:\/\/doi.org\/10.1016\/j.jcmg.2015.11.024.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1311_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijcard.2023.04.026","volume":"382","author":"JM Serrano","year":"2023","unstructured":"Serrano JM, Mata R, Gonz\u00e1lez I, et al. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. Int J Cardiol. 2023;382:52\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2023.04.026.","journal-title":"Int J Cardiol"},{"key":"1311_CR30","doi-asserted-by":"publisher","unstructured":"van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. https:\/\/doi.org\/10.1002\/14651858.CD005006.pub4","DOI":"10.1002\/14651858.CD005006.pub4"},{"issue":"4","key":"1311_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1081\/CNV-100103136","volume":"19","author":"AA Gabizon","year":"2001","unstructured":"Gabizon AA. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Invest. 2001;19(4):424\u201336. https:\/\/doi.org\/10.1081\/CNV-100103136.","journal-title":"Cancer Invest"},{"key":"1311_CR32","unstructured":"These highlights do not include all the information needed to use DEXRAZOXANE FOR INJECTION safely and effectively. See full prescribing information for DEXRAZOXANE FOR INJECTION. DEXRAZOXANE for injection, for intravenous use Initial U.S. Approval: 1995. Accessed January 11, 2025. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/be9ac1e9-21a9-439a-9029-9f03513220ea\/spl-doc?hl=dexrazoxane"},{"issue":"1","key":"1311_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. JACC CardioOncol. 2019;1(1):68\u201379. https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.003.","journal-title":"JACC CardioOncol"},{"key":"1311_CR34","doi-asserted-by":"publisher","unstructured":"de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. https:\/\/doi.org\/10.1002\/14651858.CD014638.pub2","DOI":"10.1002\/14651858.CD014638.pub2"},{"issue":"4","key":"1311_CR35","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318\u201332. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1318.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1311_CR36","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974\u201384. https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.005.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1311_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/medsci10020027","volume":"10","author":"O Lanza","year":"2022","unstructured":"Lanza O, Ferrera A, Reale S, et al. New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. Med Sci (Basel). 2022;10(2):27. https:\/\/doi.org\/10.3390\/medsci10020027.","journal-title":"Med Sci (Basel)"},{"key":"1311_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","volume":"124","author":"I Depetris","year":"2018","unstructured":"Depetris I, Marino D, Bonzano A, et al. Fluoropyrimidine-induced cardiotoxicity. Crit Rev Oncol Hematol. 2018;124:1\u201310. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"1311_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","volume":"18","author":"ME Layoun","year":"2016","unstructured":"Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Curr Oncol Rep. 2016;18(6):35. https:\/\/doi.org\/10.1007\/s11912-016-0521-1.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"1311_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","volume":"37","author":"J Kanduri","year":"2019","unstructured":"Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin. 2019;37(4):399\u2013405. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.004.","journal-title":"Cardiol Clin"},{"key":"1311_CR41","doi-asserted-by":"publisher","unstructured":"Cucciniello L, Bidoli E, Viel E, Canale ML, Gerratana L, Lestuzzi C. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity. Front Cardiovasc Med. 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.960240","DOI":"10.3389\/fcvm.2022.960240"},{"issue":"2","key":"1311_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12012-024-09834-9","volume":"24","author":"M Rajaeinejad","year":"2024","unstructured":"Rajaeinejad M, Parhizkar-Roudsari P, Khoshfetrat M, et al. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. Cardiovasc Toxicol. 2024;24(2):184\u201398. https:\/\/doi.org\/10.1007\/s12012-024-09834-9.","journal-title":"Cardiovasc Toxicol"},{"key":"1311_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","volume":"9","author":"MB Morelli","year":"2022","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, et al. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med. 2022;9: 847012. https:\/\/doi.org\/10.3389\/fcvm.2022.847012.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"1311_CR44","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704\u201312. https:\/\/doi.org\/10.1200\/JCO.1991.9.9.1704.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1311_CR45","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","volume":"30","author":"CG Tocchetti","year":"2019","unstructured":"Tocchetti CG, Cadeddu C, Di Lisi D, et al. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal. 2019;30(18):2110\u201353. https:\/\/doi.org\/10.1089\/ars.2016.6930.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"1311_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1311_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/2278-330X.126527","volume":"3","author":"N Shetty","year":"2014","unstructured":"Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer. 2014;3(1):57\u20139. https:\/\/doi.org\/10.4103\/2278-330X.126527.","journal-title":"South Asian J Cancer"},{"key":"1311_CR48","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. In: Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK); 2011. Accessed July 19, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK82853\/"},{"key":"1311_CR49","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Klijin J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131\u20139.","journal-title":"Lancet"},{"key":"1311_CR50","doi-asserted-by":"crossref","unstructured":"Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial [published correction appears in Expert Rev Anticancer Ther. 2009 Mar;9(3):388]. Expert Rev Anticancer Ther. 2009;9(1):51\u201360.","DOI":"10.1586\/14737140.9.1.51"},{"issue":"9438","key":"1311_CR51","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(04)17018-9.","journal-title":"Lancet"},{"issue":"10","key":"1311_CR52","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-116327.","journal-title":"Blood"},{"issue":"7","key":"1311_CR53","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1212\/01.wnl.0000140491.54664.50","volume":"63","author":"CD Bushnell","year":"2004","unstructured":"Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63(7):1230\u20133. https:\/\/doi.org\/10.1212\/01.wnl.0000140491.54664.50.","journal-title":"Neurology"},{"issue":"1","key":"1311_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13058-020-01319-1","volume":"22","author":"L Biganzoli","year":"2020","unstructured":"Biganzoli L, Cinieri S, Berardi R, et al. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Res. 2020;22(1):83. https:\/\/doi.org\/10.1186\/s13058-020-01319-1.","journal-title":"Breast Cancer Res"},{"issue":"28","key":"1311_CR55","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00338.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1311_CR56","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1103507.","journal-title":"N Engl J Med"},{"issue":"10218","key":"1311_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2020;395(10218):117\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(19)32955-1.","journal-title":"Lancet"},{"issue":"5","key":"1311_CR58","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Th\u00fcrlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol. 2007;25(5):486\u201392. https:\/\/doi.org\/10.1200\/JCO.2006.08.8617.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1311_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J, Inno A, de Iuliis F, et al. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clin Breast Cancer. 2017;17(1):11\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2016.07.003.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"1311_CR60","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/curroncol30020142","volume":"30","author":"JJ Yoo","year":"2023","unstructured":"Yoo JJ, Jung EA, Kim Z, Kim BY. Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis. Curr Oncol. 2023;30(2):1831\u201343. https:\/\/doi.org\/10.3390\/curroncol30020142.","journal-title":"Curr Oncol"},{"issue":"8","key":"1311_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25600","volume":"5","author":"E Lin","year":"2022","unstructured":"Lin E, Garmo H, Van Hemelrijck M, et al. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Netw Open. 2022;5(8): e2225600. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25600.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1311_CR62","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani O, Walley BA, Fleming GF, et al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023;41(7):1376\u201382. https:\/\/doi.org\/10.1200\/JCO.22.01064.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1311_CR63","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1002\/cam4.5390","volume":"12","author":"YS Chou","year":"2023","unstructured":"Chou YS, Wang CC, Hsu LF, et al. Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study. Cancer Med. 2023;12(5):5536\u201344. https:\/\/doi.org\/10.1002\/cam4.5390.","journal-title":"Cancer Med"},{"issue":"1","key":"1311_CR64","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0309","volume":"261","author":"MWS Lim","year":"2024","unstructured":"Lim MWS, Lucas-Herald AK, Mason A, Delles C, Connelly PJ. Sex differences in the cardiovascular effects of GnRH analogues. J Endocrinol. 2024;261(1): e230309. https:\/\/doi.org\/10.1530\/JOE-23-0309.","journal-title":"J Endocrinol"},{"issue":"1","key":"1311_CR65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1311_CR66","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"S Dennis","year":"2024","unstructured":"Dennis S, Oleg L, Zbigniew N, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2305488.","journal-title":"N Engl J Med"},{"issue":"5","key":"1311_CR67","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ejh.13590","volume":"106","author":"MT West","year":"2021","unstructured":"West MT, Smith CE, Kaempf A, et al. CDK 4\/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021;106(5):634\u201342. https:\/\/doi.org\/10.1111\/ejh.13590.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1311_CR68","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183(2):479\u201387. https:\/\/doi.org\/10.1007\/s10549-020-05783-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1311_CR69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","volume":"33","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, O\u2019Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616\u201327. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.006.","journal-title":"Ann Oncol"},{"key":"1311_CR70","doi-asserted-by":"publisher","unstructured":"Fiste O, Liontos M, Gavriatopoulou M, et al. CDK4\/6 inhibitors and cardiovascular toxicity: Real-world evidence. JCO. 2023;41(16_suppl):e15074-e15074. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e15074","DOI":"10.1200\/JCO.2023.41.16_suppl.e15074"},{"issue":"5","key":"1311_CR71","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","volume":"125","author":"HA Burris","year":"2021","unstructured":"Burris HA, Chan A, Bardia A, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021;125(5):679\u201386. https:\/\/doi.org\/10.1038\/s41416-021-01415-9.","journal-title":"Br J Cancer"},{"issue":"4","key":"1311_CR72","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"Lu Im Seock-Ah","year":"2019","unstructured":"Im Seock-Ah Lu, Yen-Shen BA, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"key":"1311_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","volume":"189","author":"J Alexandre","year":"2018","unstructured":"Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89\u2013103. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.009.","journal-title":"Pharmacol Ther"},{"key":"1311_CR74","doi-asserted-by":"publisher","unstructured":"Lyon A. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","DOI":"10.1093\/eurheartj\/ehac244"},{"issue":"5","key":"1311_CR75","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1002\/onco.13684","volume":"26","author":"RS Finn","year":"2021","unstructured":"Finn RS, Rugo HS, Gelmon KA, et al. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021;26(5):e749\u201355. https:\/\/doi.org\/10.1002\/onco.13684.","journal-title":"Oncologist"},{"issue":"1","key":"1311_CR76","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53\u201365. https:\/\/doi.org\/10.1002\/onco.13531.","journal-title":"Oncologist"},{"issue":"11","key":"1311_CR77","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"14","key":"1311_CR78","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"S Dennis","year":"2011","unstructured":"Dennis S, Wolfgang E, Nicholas R, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med. 2011;365(14):1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"N Engl J Med"},{"issue":"35","key":"1311_CR79","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"PA Ganz","year":"2017","unstructured":"Ganz PA, Romond EH, Cecchini RS, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31\/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. JCO. 2017;35(35):3942\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.74.1165.","journal-title":"JCO"},{"issue":"16","key":"1311_CR80","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1659\u201372. https:\/\/doi.org\/10.1056\/NEJMoa052306.","journal-title":"N Engl J Med"},{"issue":"10075","key":"1311_CR81","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 2017;389(10075):1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2.","journal-title":"The Lancet"},{"issue":"32","key":"1311_CR82","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.23.00790","volume":"41","author":"P Conte","year":"2023","unstructured":"Conte P, Bisagni G, Piacentini F, et al. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. JCO. 2023;41(32):4976\u201381. https:\/\/doi.org\/10.1200\/JCO.23.00790.","journal-title":"JCO"},{"issue":"7","key":"1311_CR83","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","volume":"26","author":"D Mavroudis","year":"2015","unstructured":"Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26(7):1333\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdv213.","journal-title":"Ann Oncol"},{"issue":"12","key":"1311_CR84","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","volume":"29","author":"P Conte","year":"2018","unstructured":"Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol. 2018;29(12):2328\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdy414.","journal-title":"Ann Oncol"},{"issue":"9555","key":"1311_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(07)60028-2.","journal-title":"Lancet"},{"issue":"1","key":"1311_CR86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9.","journal-title":"Lancet Oncol"},{"key":"1311_CR87","doi-asserted-by":"publisher","unstructured":"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | New England Journal of Medicine. Accessed May 22, 2024. https:\/\/www-nejm-org.ezproxy.uvm.edu\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1413513","DOI":"10.1056\/NEJMoa1413513"},{"issue":"2","key":"1311_CR88","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1703643.","journal-title":"N Engl J Med"},{"issue":"3","key":"1311_CR89","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdx773.","journal-title":"Ann Oncol"},{"issue":"4","key":"1311_CR90","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7932.","journal-title":"JAMA Oncol"},{"issue":"19","key":"1311_CR91","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"V Sunil","year":"2012","unstructured":"Sunil V, David M, Luca G, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"issue":"2","key":"1311_CR92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2\u2013Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. JCO. 2017;35(2):141\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.4887.","journal-title":"JCO"},{"issue":"7","key":"1311_CR93","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"issue":"5","key":"1311_CR94","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.21.00896","volume":"40","author":"IE Krop","year":"2022","unstructured":"Krop IE, Im SA, Barrios C, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2\u2013Positive Early Breast Cancer: The Phase III KAITLIN Study. JCO. 2022;40(5):438\u201348. https:\/\/doi.org\/10.1200\/JCO.21.00896.","journal-title":"JCO"},{"issue":"10371","key":"1311_CR95","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"The Lancet"},{"issue":"12","key":"1311_CR96","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709\u201318. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.004.","journal-title":"Ann Oncol"},{"key":"1311_CR97","doi-asserted-by":"publisher","unstructured":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2\u2013Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non\u2013Small-Cell Lung Cancer: TROPION-PanTumor01. Journal of Clinical Oncology. Accessed April 24, 2024. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.23.00059","DOI":"10.1200\/JCO.23.00059"},{"key":"1311_CR98","doi-asserted-by":"publisher","unstructured":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology. Accessed April 24, 2024. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1002","DOI":"10.1200\/JCO.2022.40.16_suppl.1002"},{"key":"1311_CR99","doi-asserted-by":"crossref","unstructured":"Geyer CE, Chan S, Jagiello-Gruszfeld A, Kaufman B, Davidson N, Rubin SD. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine. Published online 2006.","DOI":"10.1056\/NEJMoa064320"},{"issue":"3","key":"1311_CR100","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","volume":"166","author":"HD Choi","year":"2017","unstructured":"Choi HD, Chang MJ. Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Res Treat. 2017;166(3):927\u201336. https:\/\/doi.org\/10.1007\/s10549-017-4460-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1311_CR101","doi-asserted-by":"publisher","unstructured":"Murthy Rashmi K., Loi Sherene, Okines Alicia, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 2020;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","DOI":"10.1056\/NEJMoa1914609"},{"issue":"1","key":"1311_CR102","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10549-021-06173-z","volume":"188","author":"YH Im","year":"2021","unstructured":"Im YH, Karabulut B, Lee KS, et al. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. Breast Cancer Res Treat. 2021;188(1):77\u201389. https:\/\/doi.org\/10.1007\/s10549-021-06173-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1311_CR103","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1109653.","journal-title":"N Engl J Med"},{"issue":"7","key":"1311_CR104","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaoncol.2018.0060","volume":"4","author":"M Royce","year":"2018","unstructured":"Royce M, Bachelot T, Villanueva C, et al. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018;4(7):977\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0060.","journal-title":"JAMA Oncol"},{"key":"1311_CR105","doi-asserted-by":"publisher","unstructured":"Turner Nicholas C., Oliveira Mafalda, Howell Sacha J., et al. Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","DOI":"10.1056\/NEJMoa2214131"},{"issue":"20","key":"1311_CR106","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"A Fabrice","year":"2019","unstructured":"Fabrice A, Eva C, Gabor R, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"issue":"9","key":"1311_CR107","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"S Peter","year":"2020","unstructured":"Peter S, Javier C, Lajos P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"1311_CR108","doi-asserted-by":"publisher","unstructured":"Cortes Javier, Rugo Hope S., Cescon David W., et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2022;387(3):217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","DOI":"10.1056\/NEJMoa2202809"},{"issue":"29","key":"1311_CR109","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, Moey MYY, Cherie Tan XW, et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022;40(29):3439\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00369.","journal-title":"J Clin Oncol"},{"issue":"48","key":"1311_CR110","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42(48):4964\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehab618.","journal-title":"Eur Heart J"},{"key":"1311_CR111","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","volume":"11","author":"T Makunts","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021;11:17324. https:\/\/doi.org\/10.1038\/s41598-021-96467-5.","journal-title":"Sci Rep"},{"issue":"12","key":"1311_CR112","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1311_CR113","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.gendis.2023.01.024","volume":"11","author":"Y He","year":"2023","unstructured":"He Y, Yu H, Dai S, et al. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology Genes Dis. 2023;11(2):807\u201318. https:\/\/doi.org\/10.1016\/j.gendis.2023.01.024.","journal-title":"Perspectives from cardio-immuno-oncology Genes Dis"},{"issue":"16","key":"1311_CR114","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1311_CR115","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299\u2013311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981.","journal-title":"Circulation"},{"key":"1311_CR116","doi-asserted-by":"publisher","unstructured":"Li X, Peng W, Wu J, Yeung SCJ, Yang R. Advances in immune checkpoint inhibitors induced-cardiotoxicity. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1130438","DOI":"10.3389\/fimmu.2023.1130438"},{"key":"1311_CR117","unstructured":"Guidelines Detail. NCCN. Accessed June 18, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"1311_CR118","doi-asserted-by":"publisher","unstructured":"Schneider B. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. 2021\u201311\u201301. 39. https:\/\/doi.org\/10.1200\/JCO.21.01440","DOI":"10.1200\/JCO.21.01440"},{"issue":"8","key":"1311_CR119","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01311-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:14:41Z","timestamp":1746508481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01311-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01311-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"type":"print","value":"1527-2729"},{"type":"electronic","value":"1534-6277"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}